Peptide drugs are one of the fastest-moving areas in biotech, but behind every platform and patent is a scientist who chose to solve hard problems.
Dr. Chengzao Sun is one of those scientists.
Today, he is Co-Founder and Chief Scientific Officer at Pinnacle Medicines. He leads research in macrocyclic oral peptide therapeutics. But his path began long before the creation of the company and his role as an executive leader.
It started in a chemistry lab.
Early Education and Scientific Foundation
Dr. Sun earned his Ph.D. in Organic Chemistry from Brown University. That training shaped how he thinks.
Organic chemistry is detail-driven. It demands precision. It rewards patience.
“Chemistry teaches you discipline,” he says. “If you miss a small detail, the whole molecule fails.”
That mindset carried into his career. He focused early on peptide chemistry and synthetic methods. Peptides sit between small molecules and biologics. They are powerful but complex. For many years, they were hard to turn into practical medicines.
That challenge pulled him in.
“I’ve always liked problems that sit in the middle,” he explains. “Peptides are not easy. That’s why they’re interesting.”
How Chengzao Sun Built a Career in Peptide Drug Discovery
Over the past 20+ years, Dr. Sun has worked across biotech and large pharma. His career includes roles at Amylin, Merck, and Johnson & Johnson.
At each stop, the theme stayed the same: peptide drug discovery.
At Merck and Amylin, he worked on programs that moved from lead discovery to development. This meant designing molecules, testing their stability, and improving peptide binding to difficult biological targets.
Later, at Johnson & Johnson, he took on broader leadership. He became Head of the Peptide Platform and Early Portfolio.
That role was not just science. It was a strategy.
“You’re not just asking if a molecule works,” he says. “You’re asking if it can become a medicine.”
He led cross-functional teams. He worked with chemistry, biology, clinical, and regulatory groups. Programs moved from early research toward Phase 1, 2, and 3 clinical stages.
This shift marked a turning point. He moved from scientist to scientific leader.
Why Oral Peptide Therapeutics Matter
Peptides are powerful. But many require injection. That limits patient access and comfort.
Dr. Sun saw a gap.
“Peptides can hit targets small molecules cannot,” he explains. “But if patients can’t take them easily, adoption becomes harder.”
That problem helped shape the vision behind Pinnacle Medicines.
Today, as Co-Founder and CSO, he leads research focused on macrocyclic and oral peptide platforms. Macrocyclic peptides are structured in ways that can improve stability and binding strength. The goal is to unlock new therapeutic pathways.
His work spans multiple disease areas. These include immunology, oncology, cardiometabolic disease, and neuroscience.
He is also listed as an inventor on numerous patents related to peptide and macrocyclic therapeutics. Some focus on pathways such as interleukin-23 (IL-23), a key player in inflammatory and autoimmune diseases.
“Oral peptide may be the ultimate solution,” he says. “It is safe, efficacious and convenient”
From Big Pharma to Company Creation
Starting a company is different from leading a division inside a global pharmaceutical firm.
At Pinnacle Medicines, Dr. Sun is helping shape both science and culture.
“In a smaller company, every decision counts,” he says. “You don’t hide behind structure. You build it.”
As CSO, he oversees research direction, platform development, and scientific partnerships. He works closely with teams pushing programs from concept through early development.
The focus is not speed for its own sake. It is disciplined progress.
“Drug discovery takes time,” he says. “You have to respect biology and we focus most on validated ones.”
Publications, Patents, and Industry Impact
Dr. Sun has authored and co-authored peer-reviewed publications. His work includes advances in cyclic peptide linker design and molecular modeling.
He is also an inventor on multiple patents. These patents reflect years of applied research. They are not theoretical exercises. They are tied to real programs and real therapeutic goals.
His expertise sits at the intersection of medicinal chemistry, peptide engineering, and translational development.
Beyond corporate work, he serves as a Scientific Advisory Board member of the Boulder Peptide Society. The organization brings together researchers focused on peptide science and innovation.
“Science moves faster when people share ideas,” he says. “Community matters.”
Leadership Style and Industry Perspective
Dr. Sun does not describe himself as a visionary. He describes himself as practical.
“You earn credibility molecule by molecule,” he says.
Colleagues know him for bridging detailed chemistry with business strategy. That combination matters in biotech. A platform must work scientifically. But it must also fit development realities.
He believes the peptide field is entering a new phase.
“We now have better tools,” he says. “Computational design. Improved synthesis. Better delivery strategies. The field is more mature.”
Still, he stays cautious.
“Drug discovery humbles you,” he says. “You learn to stay curious.”
The Bigger Picture in Peptide Innovation
Peptide drug discovery is no longer a niche. It is a competitive and fast-evolving sector within biotech.
Leaders like Dr. Chengzao Sun helped build the foundation during its early phases. Now they are shaping their next chapter.
His career shows a steady progression: chemist, drug discovery scientist, platform head, co-founder.
Each step builds on the last.
“I never chased titles,” he says. “I chased hard scientific questions.”
Today, those questions continue at Pinnacle Medicines.
And the molecules are still at the center of the story.
Read more:
Dr. Chengzao Sun: Building the Future of Peptide Drugs
